The pursuit of market outperformance leads investors to the practice of hand-picking stocks. Skillful choices can be a catalyst for significant wealth enhancement.
Sarepta Therapeutics Inc (NASDAQ: SRPT) closed the day trading at $17.11 down -0.70% from the previous closing price of $17.23. In other words, the price has decreased by -$0.70 from its previous closing price. On the day, 4.72 million shares were traded. SRPT stock price reached its highest trading level at $17.69 during the session, while it also had its lowest trading level at $16.97.
Ratios:
For a better understanding of SRPT, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 2.46 and its Current Ratio is at 4.02. In the meantime, Its Debt-to-Equity ratio is 1.18 whereas as Long-Term Debt/Eq ratio is at 1.18.
On June 18, 2025, TD Cowen Downgraded its rating to Hold which previously was Buy but kept the price unchanged to $24.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Mar 12 ’25 when Nicaise Claude sold 2,491 shares for $99.64 per share. The transaction valued at 248,203 led to the insider holds 27,812 shares of the business.
Nicaise Claude bought 2,491 shares of SRPT for $248,226 on Mar 12 ’25. On Dec 12 ’24, another insider, Wigzell Hans Lennart Rudolf, who serves as the Director of the company, sold 10,500 shares for $124.84 each. As a result, the insider received 1,310,820 and left with 22,840 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, SRPT now has a Market Capitalization of 1681519488 and an Enterprise Value of 2515481088. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.75 while its Price-to-Book (P/B) ratio in mrq is 1.47. Its current Enterprise Value per Revenue stands at 1.126 whereas that against EBITDA is -32.146.
Stock Price History:
The Beta on a monthly basis for SRPT is 0.49, which has changed by -0.8908453 over the last 52 weeks, in comparison to a change of 0.12748289 over the same period for the S&P500. Over the past 52 weeks, SRPT has reached a high of $162.95, while it has fallen to a 52-week low of $16.99. The 50-Day Moving Average of the stock is -57.71%, while the 200-Day Moving Average is calculated to be -81.67%.
Shares Statistics:
Over the past 3-months, SRPT traded about 5.17M shares per day on average, while over the past 10 days, SRPT traded about 11781730 shares per day. A total of 98.25M shares are outstanding, with a floating share count of 93.47M. Insiders hold about 4.99% of the company’s shares, while institutions hold 90.07% stake in the company. Shares short for SRPT as of 1749772800 were 9885949 with a Short Ratio of 1.91, compared to 1747267200 on 8826498. Therefore, it implies a Short% of Shares Outstanding of 9885949 and a Short% of Float of 11.790000000000001.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
Its stock is currently analyzed by 12.0 different market analysts. The consensus estimate for the next quarter is $0.35, with high estimates of $1.64 and low estimates of -$2.01.
Analysts are recommending an EPS of between $2.73 and -$6.37 for the fiscal current year, implying an average EPS of -$1.89. EPS for the following year is $3.65, with 14.0 analysts recommending between $10.46 and -$5.46.
Revenue Estimates
18 analysts predict $530.66M in revenue for the current quarter. It ranges from a high estimate of $646.48M to a low estimate of $411.3M. As of the current estimate, Sarepta Therapeutics Inc’s year-ago sales were $362.93MFor the next quarter, 18 analysts are estimating revenue of $498.91M. There is a high estimate of $780.1M for the next quarter, whereas the lowest estimate is $357.43M.
A total of 22 analysts have provided revenue estimates for SRPT’s current fiscal year. The highest revenue estimate was $2.82B, while the lowest revenue estimate was $1.88B, resulting in an average revenue estimate of $2.27B. In the same quarter a year ago, actual revenue was $1.9BBased on 23 analysts’ estimates, the company’s revenue will be $2.28B in the next fiscal year. The high estimate is $3.88B and the low estimate is $1.16B.
